Navigation Links
U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'RESUS' Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Date:3/23/2009

CAMBRIDGE, Mass., March 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the U.S. Naval Medical Research Center (NMRC) has submitted to the Food and Drug Administration (FDA) a revised investigational new drug (IND) application to conduct a clinical trial of the company's oxygen therapeutic Hemopure(R) [hemoglobin glutamer - 250 (bovine)] for the pre-hospital treatment of trauma patients. The study is entitled "Restore Effective Survival in Shock" (RESUS). The RESUS trial was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission was placed on clinical hold.

Under a research agreement with Biopure, the NMRC assumed primary responsibility, subject to funding, for designing, seeking FDA acceptance of and directing a trial for Hemopure's prehospital used in trauma patients with hemorrhagic shock. The NMRC has developed protocols for trials in civilian casualties in the United States and abroad (RESUS) as well as a trial proposed to be conducted in the field, called Operation RESUS (OP RESUS). To date, Congress has appropriated funds for the development of Hemopure for potential use in military and civilian trauma indications and to cover military administrative costs. This funding is being used for trial preparation and for preclinical studies of Hemopure in animal models, including those that mimic military trauma scenarios.

As previously reported, in June 2008 the NMRC submitted and subsequently withdrew an Op RESUS protocol for a Phase 2 clinical trial of Hemopure for resuscitation of operations casualties with severe traumatic hemor
'/>"/>

SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) today announced that it ... FDA Panel meeting on Monday, May 10, 2010 at ... . Don Bailey , President and Chief Executive Officer; Steve ... , Chief Science Officer; and Dr. Jason Zielonka , Senior Vice President ...
... , May 3 Watson Pharmaceuticals, Inc. (NYSE: WPI ... Watson,s president and chief executive officer, will provide an overview and update of ... Tuesday, May 11, 2010 at 1:40pm Eastern Daylight Time ... , , ...
Cached Medicine Technology:Questcor to Discuss Results From FDA Panel Meeting 2Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference 2
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business in ... from ingredients sourced all over the world, then manufactured into specific formulations in ... developed the highest-quality oils in the industry, which we are bringing to consumers ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... PHILADELPHIA Scientists and clinicians from around the ... at the American Association for Cancer Researchs second ... Development. The conference is subtitled Maximizing Opportunities for ... diagnostics to provide new strategies for tailoring therapies ...
... LOMA LINDA, Calif., Sept. 10 Loma ... Day Adventist institution located,in Southern California, has ... physician referrals and outbound reminder calls for ... seeking physician referrals for breast care, psychology, ...
... Harvard Medical School,researchers have honored BlueCross BlueShield of ... providers to obtain member pre-,certifications in seconds over ... less costly. Researchers from the medical school,s ... tool as one of seven national,BlueWorks(R) winners in ...
... ABBOTT PARK, Ill., Sept. 10 Abbott (NYSE:,ABT) ... named to the Dow Jones,Sustainability World Index and ... third consecutive year. This selection recognizes Abbott,s,continued leadership ... is a critical part of our approach to ...
... ATLANTA, Sept. 10 Coalition America, Inc. (CAI),announces ... strategy officer who,will lead the deployment efforts of ... continuous new product development,initiatives. Brown comes to ... the,healthcare industry having held management roles in various ...
Cached Medicine News:Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Scientists, physicians present latest findings in 'personalized' cancer treatment and prevention 2Health News:Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Women's Services Programs and Departments 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2Health News:Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer 2
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Medicine Products: